DNA依赖性蛋白激酶抑制剂peposertib增强177Lu放射免疫治疗在前列腺癌和肾细胞癌临床前模型中的疗效
在SK-RC-52肾细胞癌和LNCaP前列腺癌小鼠移植瘤模型中,评估177Lu-DOTA-girentuximab或177Lu-DOTA-rosopatamab单用或联合peposertib的疗效。联合peposertib可增强抗肿瘤效果并增加DNA双链断裂,在SK-RC-52模型中177Lu-DOTA-girentuximab(6 MBq)联合peposertib组达4/4完全缓解。
要点
- Peposertib单药无显著抗肿瘤效果,但可增强177Lu放射免疫治疗的疗效。
- SK-RC-52模型中177Lu-DOTA-girentuximab(6 MBq)联合peposertib组达4/4完全缓解。
- LNCaP模型中177Lu-DOTA-rosopatamab(6 MBq)联合peposertib组达3/4完全缓解。
核心结论
- Peposertib与177Lu放射免疫治疗联合在肾细胞癌和前列腺癌临床前模型中耐受良好。
- 研究结果提示peposertib与177Lu放射免疫治疗之间存在协同效应,peposertib增强了放射免疫治疗的疗效。
- 这种协同作用提示有可能降低有效癌症治疗所需的放射免疫治疗剂量。
研究设计与样本
- 在SK-RC-52肾细胞癌和LNCaP前列腺癌小鼠移植瘤模型中,分别使用177Lu-DOTA-girentuximab(靶向碳酸酐酶IX)或177Lu-DOTA-rosopatamab(靶向前列腺特异性膜抗原)经单次静脉给药(3或6 MBq)递送β射线。
- Peposertib(50 mg/kg,每日一次,共14天)经口灌胃给药。
- 对两种临床前模型均进行了177Lu放射免疫治疗的生物分布和体内成像,监测肿瘤生长和体重至终点,并通过肿瘤切片中γH2AX焦点形成分析DNA双链断裂。
主要发现
- 离体生物分布和体内SPECT/MRI显示每种放射性药物均有良好的肿瘤摄取。
- 所有治疗组小鼠体重稳定。
- Peposertib单药未显示显著抗肿瘤效果。
- 在SK-RC-52动物模型中,177Lu-DOTA-girentuximab联合peposertib较177Lu-DOTA-girentuximab单药显示增强的抗肿瘤疗效,177Lu-DOTA-girentuximab(6 MBq)联合peposertib组达4/4完全缓解。
- 在LNCaP前列腺癌模型中,177Lu-DOTA-rosopatamab(6 MBq)联合peposertib组达3/4完全缓解;peposertib联合低剂量177Lu-DOTA-girentuximab(3 MBq)的抗肿瘤活性与177Lu-DOTA-girentuximab(6 MBq)单药相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel radiation sensitizers, including inhibitors targeting DNA damage response, have been developed to enhance the efficacy of anticancer treatments that induce DNA damage in cancer cells. Peposertib, a potent, selective, and orally administered inhibitor of DNA-dependent protein kinase, impedes the nonhomologous end-joining mechanism for DNA double-strand break (DSB) repair. We investigated radioimmunotherapy alone or with peposertib in preclinical models of renal cell carcinoma (RCC) or prostate cancer. Methods: 177Lu-DOTA-girentuximab (targeting carbonic anhydrase IX) or 177Lu-DOTA-rosopatamab (targeting prostate-specific membrane antigen) was used to deliver β-radiation to tumors via a single intravenous dose (3 or 6 MBq) in mice bearing SK-RC-52 RCC or LNCaP prostate cancer xenografts, respectively. Peposertib (50 mg/kg daily for 14 d) was administered via oral gavage. Biodistribution and in vivo imaging of 177Lu-based radioimmunotherapy were performed for both preclinical models. Tumor growth and body weight were monitored until the endpoint. Assessment of DNA damage was performed by measuring DSBs through analysis of γH2AX foci formation in tumor sections. Results: Ex vivo biodistribution and in vivo SPECT/MRI revealed excellent tumor uptake of each radiopharmaceutical. Mouse body weight was stable in all treatment arms. Peposertib alone did not show a significant antitumor effect. The addition of peposertib to 177Lu-DOTA-girentuximab showed enhanced antitumor efficacy compared with 177Lu-DOTA-girentuximab alone in the SK-RC-52 animal model, with a 4 of 4 complete response rate in the 177Lu-DOTA-girentuximab (6 MBq) plus peposertib arm. Peposertib combined with low-dose 177Lu-DOTA-girentuximab (3 MBq) demonstrated antitumor activity comparable to 177Lu-DOTA-girentuximab (6 MBq) monotherapy. In the LNCaP prostate cancer model, the combination of 177Lu-DOTA-rosopatamab (6 MBq) and peposertib achieved a 3 of 4 complete response rate. Increased DSBs were observed with the addition of peposertib to 177Lu-based radioimmunotherapy. Conclusion: The combination of peposertib with 177Lu-based radioimmunotherapy was well tolerated in preclinical models of RCC and prostate cancer. Our findings suggest a synergistic effect between peposertib and 177Lu-based radioimmunotherapy, wherein peposertib enhanced the efficacy of radioimmunotherapy. This synergy indicates the potential to reduce the necessary dose of radioimmunotherapy for effective cancer treatment.
引用
- Johnstone CN, Osellame LD, Cao Z, et al. DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. J Nucl Med. 2025. PMID: 39884775. doi:10.2967/jnumed.124.268695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。